Inhaltsbereich
| 16 Einträge |
Seite 1 / 1
 Druckansicht
|
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. |
| Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep 17. pii: mdu456. doi: 10.1093/annonc/mdu456 |
| PMID: 25231953 |
| Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. |
| Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI |
| Journal of the National Cancer Institute. 2013 Feb 19. pii: djt026. doi: 10.1093/jnci/djt026 |
| PMID: 23425564 |
| Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. |
| Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2003 Nov 21. |
| PMID: 14630678 |
| Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. |
| Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 23. doi: 10.1200/JCO.2016.69.2871 |
| PMID: 28113032 |
| Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial. |
| Baselga J, Campone M, Piccart-Gebhart MJ, Burris HA, Rugo HS, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley DA, Deleu I, Perez A, Bachelot TD, Vittori L, Mukhopadhyay P, Weber D, Sahmoud T, Hortobagyi GN |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jan 1. pii: 10.1200/jco.2011.29.15_suppl.e11058 |
| PMID: 28023426 |
| Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). |
| Díaz-Rubio E, Burris H, Douillard JY, Coxon FY, Maughan T, Bertetto O, Schueller J, Husseini F, Marschner N, Scheithauer W |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Jan 1. pii: 10.1200/jco.2004.22.14_suppl.3737 |
| PMID: 28013721 |
| Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. |
| Campone M, Lebrun F, Noguchi S, Pritchard KI, Burris HA, Beck JT, Ito Y, Bachelot T, Pistilli B, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Litton JK, Brechenmacher T, El-Hashimy M, Taran T, Gnant M |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 31. doi: 10.1200/jco.2013.31.26_suppl.151 |
| PMID: 28136563 |
| Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). |
| Baselga J, Rugo HS, Noguchi S, Pritchard KI, Burris HA, Piccart-Gebhart MJ, Eakle JF, Mukai H, Iwata H, El-Hashimy M, Rao S, Panneerselvam A, Taran T, Hortobagyi GN, Sahmoud T, Lebwohl DE, Gnant M |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 1. doi: 10.1200/jco.2012.30.27_suppl.102 |
| PMID: 28146729 |
| Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2. |
| Burris HA, Gnant M, Baselga J, Piccart-Gebhart MJ, Noguchi S, Dakhil SR, Srimuninnimit V, Puttawibul P, Csoszi T, Heng DY, Bourgeois H, Gonzalez-Martin A, Osborne K, Mukhopadhyay P, Taran T, Campone M, Hortobagyi GN, Sahmoud T, Pritchard KI |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 1. doi: 10.1200/jco.2012.30.27_suppl.104 |
| PMID: 28146724 |
| BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. |
| Beck JT, Baselga J, Noguchi S, Gnant M, Lebrun F, Neven P, Nunzi M, Komorowski A, Chouinard E, Young RR, Anderson I, Bennett L, Ricci JF, Hortobagyi GN, Sahmoud T, Burris HA |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 1. doi: 10.1200/jco.2012.30.27_suppl.125 |
| PMID: 28146707 |
| Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. |
| Noguchi S, Pritchard KI, Burris HA, Rugo HS, Gnant M, Hortobagyi GN, Latini L, Yardley DA, Melichar B, Petrakova K, Harb W, Feng W, Cahana A, Taran T, Campone M, Baselga J, Sahmoud T, Lebwohl DE, Piccart-Gebhart MJ |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 1. doi: 10.1200/jco.2012.30.27_suppl.99 |
| PMID: 28146687 |
| Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. |
| Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Mortazavi A, Vaughn DJ, Isaacs RE, Parker K, Chen X, Yu K, Porter D, Sharma S, Graus Porta D, Bajorin DF |
| Cancer discovery. 2018 May 30. pii: 2159-8290.CD-18-0229. doi: 10.1158/2159-8290.CD-18-0229 |
| PMID: 29848605 |
| Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC). |
| Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris H |
| Annals of oncology : official journal of the European Society for Medical Oncology. pii: S0923-7534(19)48950-3. doi: 10.1093/annonc/mdy281.032 |
| PMID: 32136284 |
| Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. |
| Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Mar 10. pii: S0923-7534(19)36498-1. doi: 10.1093/annonc/mdu009. pmc: PMC3969554 |
| PMID: 24615500 |
| Extended RAS Analysis of the Phase 3 EPIC Trial: Irinotecan + Cetuximab vs Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. |
| Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris H |
| The oncologist. 2020 Nov 15. doi: 10.1002/onco.13591 |
| PMID: 33191588 |
| 16 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
